Invitation to presentation of Sedana Medical’s interim report for the first quarter 2023
Sedana Medical AB (publ) plans to present its interim report for the first quarter of 2023 on Thursday April 27 at 13:30 CET.
According to the financial calendar, Sedana Medical plans to publish the interim report for the first quarter 2023 on Thursday April 27 at approximately 07.00 CET. Sedana Medical hereby invites to a presentation of the report on the same day, where the CEO Johannes Doll will present the report in English together with Johan Spetz, CFO, and Peter Sackey, CMO, as well as answer questions.
Date: Thursday, April 27, 2023
Time (CET): 13:30
More info and link to the audiocast: https://financialhearings.com/event/45893
For additional information, please contact:
Johannes Doll, CEO, +46 (0)76 303 66 66
Johan Spetz, CFO, +46 (0)730 36 37 89
About Sedana Medical
Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.
Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.
Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm (SEDANA) and headquartered in Stockholm, Sweden.